EVROFConsumer Defensive · Packaged Foods · ΧΑ
Evrofarma
€3.71
−0.12(−3.13%)
Close 08/10/2026 · end-of-day price, not real-time
Evrofarma (EVROF) closed at €3.71 on 08/10/2026, -3.13% on the day. Market cap €52.9m, P/E 49.11, dividend yield 1.62%.
My view
Private · MENTOR takes it into account
+12.4%6M
08/10/2026Close 3.71−3.13%Vol 5.2k+12.4% since start
Valuation
Peers: 5| Metric | EVROF | Peer median |
|---|---|---|
| P/E | 49.1 | 14.3 |
| P/E (forward) | — | 13.6 |
| P/B | 2.3 | 2.4 |
| P/S | 1.0 | 1.5 |
| EV/EBITDA | 8.7 | 10.7 |
| Dividend yield | 1.6% | 2.4% |
| Payout ratio | — | 37.7% |
| Gross margin | — | 32.9% |
| Operating margin | 12.3% | 12.2% |
| Net margin | 8.4% | 8.4% |
| ROE | 20.2% | 18.0% |
| Revenue growth (quarter, y/y) | 8.8% | 10.3% |
| Net debt | €12.4m | €20.5m |
Twelve Data · latest quarter 31/12/2025
Same sector: Consumer Defensive
Mkt capEV/EBITDAP/EDay
Coca-Cola HBCEEE€18.2bn11.018.4+0.6%Karelia TobaccoKARE€1.2bn2.78.3−0.5%Kri-Kri Milk IndustryKRI€1.1bn16.621.8−2.0%SarantisSAR€742.7m10.314.0+0.7%PapoutsanisPAP€93.5m10.714.3−1.2%EvrofarmaEVROF€52.9m8.749.1−3.1%
The company
AI-draftedEvrofarma produces milk, yogurt and cheese in Thrace for Greece and export markets. Wholly owned Campus raises cattle and produces milk. The group combines farming and processing, with substantial exposure to one large customer.
How it makes moneyFY2025 · basis: revenue
It is
Recent developmentsAll company events →
- Sep 2026New board appointed, with three independent members out of seven.3,5
- Sep 2026The FY2025 dividend was set at €0.0601276633 gross per eligible share after the treasury adjustment, with payment announced from September 22.4
- Aug 2026Treasury shares reached 29,031, or 0.2123% of issued capital.6
- Apr 2026Completion of a €7.2m first-quarter investment was announced, mainly expanding the strained-yogurt line.2
- Nov 2025A programme to acquire up to 683,660 treasury shares began, running through August 5 2027.8
- Sep 2025The new Greek legal name took effect on the exchange.9
Key figures
Key facts
- The group employed 178 people at the end of 2025.1
- The new board took office on September 4 2026, with Panagiotis Papazilakis as chair.3
- FY2025 operating cash flow was €3.590m, while investment grants received were €3.580m.1
- H1 2026 results were scheduled for September 25 and are not included in this research.7
Sources
- 1.Annual financial report FY2025Evrofarma S.A. · 17/04/2026official
- 2.FY2025 results release EnglishEvrofarma S.A. · 17/04/2026official
- 3.New board and committees corrected notice dated September 4, republished September 7Evrofarma S.A. · 07/09/2026official
- 4.FY2025 dividend corrected notice dated September 4, republished September 7Evrofarma S.A. · 07/09/2026official
- 5.Annual general meeting decisions September 4 2026Evrofarma S.A. · 04/09/2026official
- 6.Treasury shares held after August 21 purchasesEvrofarma S.A. · 21/08/2026official
- 7.Amended financial calendar 2026Evrofarma S.A.official
- 8.Launch of treasury share programmeEvrofarma S.A. · 10/11/2025official
- 9.Greek legal name and title changeEvrofarma S.A. · 29/08/2025official
- 10.Campus standalone annual financial report FY2025Evrofarma S.A.official
- 11.ESMA FIRDS current XATH instrument recordESMAofficial
AI-drafted from the cited sources · 24/09/2026 · v1 · ✓ checked by an independent second modelEvrofarma S.A.Website ↗
AskedSuggested
Why it moved
-3.13% · volume 1.2×
News & events
News and what's next
Peers
5 listed peers
Results
How it did vs last year
Valuation
Cheap or expensive?
More
Asks“Why did Evrofarma fall 3.13%?”← → to move · Enter to ask
Data: Twelve Data · End-of-day prices · Nothing here is investment advice.